3SBio Attracts GIC, BlackRock to $712 Million Hong Kong IPO
May 26, 2015

By Fox Hu of BloombergBusiness

3SBio Inc., a Chinese producer of biopharmaceutical products, and its private-equity backer are seeking as much as $712 million from a Hong Kong initial public offering.

The company, based in the northeastern Chinese city of Shenyang, and an arm of Citic Private Equity Funds Management Co. are offering 606.1 million shares at HK$8.30 to HK$9.10 apiece, according to terms for the deal obtained by Bloomberg. New shares account for 80 percent of the sale, the terms show.

3SBio is adding to the $11.9 billion of first-time share sales in Hong Kong this year after the city’s stock market surged to a seven-year high on an influx of Chinese money. The company’s products are used to counteract the side effects of chemotherapy in cancer patients and treat anemia in people suffering from chronic kidney disease.

The company, which was taken private two years ago, is seeking a valuation of as much as $2.85 billion from relisting in Hong Kong. The figure is more than seven times 3SBio’s value when it last traded on the Nasdaq market in May 2013, data compiled by Bloomberg show.

Six cornerstone investors agreed to buy a total of $150 million in stock in the offering. Singapore sovereign wealth fund GIC Pte will invest $30 million, while BlackRock Inc. funds have committed to buy $40 million of shares, the terms show.

Citic Securities Co., Goldman Sachs Group Inc. and Morgan Stanley are joint sponsors of the offering. 3SBio plans to use 45 percent of the proceeds to fund acquisitions that will expand its pharmaceutical portfolio in therapeutic areas, according to the terms. 3SBio aims to price the offering on June 4 and start trading a week later.

Copyright ? 2011 Decheng Capital LLC. All Rights Reserved.
浙江20选5预测推荐 新疆11选5任选基本走势图 星悦浙江麻将游戏 组选号944历史开奖号 网赌ds视讯有假吗 广东快乐十分精准计划 北京11选5彩票助手 秒速赛车玩法攻略贴吧 易方达易理财收益 扑克麻将技巧 中奖号码查询器 尊龙线上娱乐平台 超级大乐透免费预测 山西11选5走势图基本走势图 篮彩推荐预测 天津11选5手机号码 以太币2021年价格